The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: An Italian healthcare payer perspective

被引：0
|
作者：
Patterson, K. [1 ]
Bhattacharyya, S. [1 ]
Personeni, N. [2 ]
Gebbia, V. [3 ]
Novelli, P. [4 ]
Di Matteo, S. [5 ]
Colombo, G. [6 ]
Pescott, C. [7 ]
机构：
[1] BresMed, Hlth Econ, Sheffield, S Yorkshire, England
[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[3] Univ Palermo, La Maddalena Hosp, Palermo, Italy
[4] Merck Serono SpA, HTA & Market Access, Rome, Italy
[5] SAVE Studi Anal Valutaz Econ srl, Hlth Econ & Outcomes Res, Milan, Italy
[6] Univ Pavia, Dept Drug Sci, Pavia, Italy
[7] Merck Healthcare KGaA, Global Evidence & Value Dev, Darmstadt, Germany
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
596P
引用
收藏
页码：225 / 225
页数：1
相关论文
共 50 条
  • [41] The impact of toxicity and efficacy on quality of life in KRAS wild-type metastatic colorectal cancer patients treated with first-line chemotherapy plus cetuximab
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Von Hohnhorst, P.
    Esser, R.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S518 - S518
  • [42] Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
    Kim, Sang-A
    Park, Hyejoo
    Kim, Kui-Jin
    Kim, Ji-Won
    Sung, Ji Hea
    Nam, Milang
    Lee, Ju Hyun
    Jung, Eun Hee
    Suh, Koung Jin
    Lee, Ji Yun
    Kim, Se Hyun
    Lee, Jeong-Ok
    Kim, Jin Won
    Kim, Yu Jung
    Kim, Jee Hyun
    Bang, Soo-Mee
    Lee, Jong Seok
    Lee, Keun-Wook
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [43] Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
    Sang-A Kim
    Hyejoo Park
    Kui-Jin Kim
    Ji-Won Kim
    Ji Hea Sung
    Milang Nam
    Ju Hyun Lee
    Eun Hee Jung
    Koung Jin Suh
    Ji Yun Lee
    Se Hyun Kim
    Jeong-Ok Lee
    Jin Won Kim
    Yu Jung Kim
    Jee Hyun Kim
    Soo-Mee Bang
    Jong Seok Lee
    Keun-Wook Lee
    Scientific Reports, 11
  • [44] First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
    Muro, K.
    Watanabe, J.
    Shitara, K.
    Yamazaki, K.
    Ohori, H.
    Shiozawa, M.
    Yasui, H.
    Oki, E.
    Sato, T.
    Naitoh, T.
    Komatsu, Y.
    Kato, T.
    Hihara, M.
    Soeda, J.
    Yamamoto, K.
    Akagi, K.
    Ochiai, A.
    Uetake, H.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S377 - S377
  • [45] Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
    Chan, Wing-Lok
    Lee, Victor Ho Fun
    Siu, Wai Kwan Steven
    Ho, Pui Ying Patty
    Liu, Rico King Yin
    Leung, To Wai
    SOUTH ASIAN JOURNAL OF CANCER, 2014, 3 (03) : 175 - 178
  • [46] COST-EFFECTIVENESS ANALYSIS OF CETUXIMAB AND PANITUMUMAB AS FIRST-LINE THERAPIES FOR METASTATIC COLORECTAL CANCER IN SPAIN
    Moreno, V
    Martinez-Amores, B.
    Barriuso, J.
    Mezquita, L.
    Ibanez de Caceres, I.
    Ayuso, A.
    Pena, J. M.
    Perona, R.
    Grande, E.
    Belda-Iniesta, C.
    VALUE IN HEALTH, 2012, 15 (07) : A421 - A422
  • [47] CANADIAN ECONOMIC ANALYSIS OF BEVACIZUMAB, CETUXIMAB, AND PANITUMUMAB IN THE FIRST LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)
    Lawrence, D.
    Maschio, M.
    Yunger, S.
    Easaw, J.
    Aucoin, N.
    Weinstein, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 202 - 202
  • [48] Emergence of RAS mutations in RAS wild type metastatic colorectal cancer patients receiving cetuximab as first-line treatment: A prospective study.
    Tsai, Hsiang-Lin
    Wang, Jaw-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 38 - 38
  • [49] Cost-effectiveness analysis of cetuximab and panitumumab as first-line metastatic colorectal cancer therapies in Spain
    Moreno, Victor
    Martinez-Amores, Brezo
    Barriuso, Jorge
    Mezquita, Laura
    Ibanez de Caceres, Inmaculada
    Ayuso Sacido, Angel
    Maria Pena, Jose
    Perona, Rosario
    Belda-Iniesta, Cristobal
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costs
    Giuliani, Jacopo
    Bonetti, Andrea
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (03) : 243 - 248
12345